Home | Product Development | Corporate Information | Picture Gallery | Careers | Contact Us | Employee Login
 
 
 
  Our Products
  All Products
List of Generics
  Therapeutic Classes
 
CORE BRANDS
 
PRODUCT
Pozemet
 
Generic:
Metformin HCl
 
Therapeutic Class:
Antidiabetic
 
Composition:

Pozemet Tab 15 mg/500 mg

Each tablet contains 15 mg pioglitazone hydrochloride with 500 mg metformin hydrochloride.

 

Pozemet Tab 15 mg/850 mg

Each tablet contains 15 mg pioglitazone hydrochloride with 850 mg metformin hydrochloride.
 
Description:

Pozemet tablet contains two oral antihyperglycemic drugs, pioglitazone hydrochloride and metformin hydrochloride. They are used in the management of type 2 diabetes.

 

Pioglitazone hydrochloride acts primarily by decreasing insulin resistance. It improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis. It reduces circulating insulin levels and improves glycemic control.

 

Metformin hydrochloride improves glucose tolerance by lowering both basal and postprandial plasma glucose. It improves insulin sensitivity by increasing peripheral glucose uptake and utilization. It also decreases hepatic glucose production and intestinal absorption of glucose.


 
Indications:

Pozemet is indicated as an adjunct to diet and exercise to improve glycemic control in type 2 diabetic patients who are already treated with a combination of pioglitazone and metformin or whose diabetes is not adequately controlled with metformin alone or for those patients who have initially responded to pioglitazone alone and require additional glycemic control.

 
Dosage:

Starting dose of Pozemet should be based on the patient�s current treatment of pioglitazone and/or metformin. Pozemet should be given with meals in divided daily doses to reduce the gastrointestinal side effects associated with metformin.

Starting dose

For patients inadequately controlled on metformin monotherapy

Pozemet  may be initiated at either 15 mg/500 mg or 15 mg/850 mg tablet strength based on usual starting dose of pioglitazone (15-30 mg daily), once or twice daily and gradually titrated after assessing adequacy of therapeutic response.

For patients who initially responded to pioglitazone monotherapy & require additional glycemic control

Pozemet may be initiated at either 15 mg/500 mg twice daily or 15 mg/850 mg tablet strength once daily based on the usual starting doses of metformin (500 mg twice daily or 850 mg daily) and gradually titrated after assessing adequacy of therapeutic response.

For patients switching from combination therapy of pioglitazone plus metformin as separate tablets

Pozemet may be initiated with either 15 mg/500 mg or 15 mg/850 mg tablet strengths based on the dose of pioglitazone and metformin already being taken.

Maximum Recommended Dose

The maximum recommended dose for pioglitazone is 45 mg & metformin is 2,550 mg daily in adults.

 
Presentations:

Pozemet 15 mg/500 mg is available in 14’s

Pozemet 15 mg/850 mg is available in 14’s